Promethera is committed to develop life-changing new cell therapies for patients suffering from serious liver diseases. As an innovator in the emerging field of cell-based medicines, Promethera is driven by the ambition of creating a diverse portfolio of drug candidates with partners and on our own account. This vision has attracted a broad range of European and Asian institutional and corporate investors throughout the Company’s development steps as a privately-held organization.
* Essentially HNWI and private investors
** up to 11,2% after conversion of receivable in 2018 or earlier
Promethera has garnered the support of important corporate venture funds including Shire, Boehringer Ingelheim, Mitsui, Mitsubishi and specialized biotech investors such as Vesalius Biocapital and Fund+. Most recently the company gained capital from strategic Japanese and Korean investors, further enabling Promethera’s vision of treating patients worldwide.
Since inception, Promethera has raised EUR 48.6 million raised in equity not including non-dilutive support from the Walloon region of Belgium through grants and recoverable cash advances.
Current Investors overview
- Vesalius Biocapital (Lead investor)
- Boehringer Ingelheim Venture Fund
- MGI Global Fund (Mitsui)
- SMS Investment
- Mitsubishi UFJ Capital
- LifeLiver Co., Ltd.
- Cell Innovation Partners, L.P. (CIP)
- Hopp Family (Weinheim GmbH & Co KG)
- Vives Fund
- Start-up SA
- PALL Life Sciences